Analysis of U.S. Patent 3,998,834: Scope, Claims, and Patent Landscape
What does U.S. Patent 3,998,834 cover?
U.S. Patent 3,998,834, granted on December 21, 1976, relates to a pharmaceutical compound and its use, specifically targeting a class of arylamine compounds. The patent claims the synthesis, chemical structure, and therapeutic application of these compounds, primarily aimed at treating central nervous system (CNS) disorders.
Key Claim Characteristics
- Claim 1: Defines a class of arylamine compounds with a general formula involving a phenyl or naphthyl group linked to specific substituents.
- Claims 2–10: Specify particular compounds within the class, including their chemical structures and variations.
- Claims 11–15: Cover the methods of synthesizing the compounds.
- Claims 16–19: Focus on pharmaceutical compositions containing the compounds.
- Claims 20–22: Describe therapeutic methods employing the compounds for CNS disorders, including depression and psychosis.
Scope Analysis
The claims primarily encompass the chemical class of compounds with specific substitutions, methods of synthesis, and therapeutic uses. The structure-based claims are broad for the chemical class but narrow in the specifics of substituents. The patent explicitly claims both the compounds and their pharmaceutical compositions, limiting claims to use in CNS treatment.
Patent Term and Expiry
Given its filing date (March 20, 1974), the patent would have expired on March 20, 1992, based on a 17-year term from grant, or possibly earlier if patent term extensions or adjustments apply.
How does the claims’ scope compare to similar patents?
| Aspect |
Patent 3,998,834 |
Typical CNS compound patents (e.g., patent on SSRIs) |
| Chemical scope |
Class-based, covering a broad compound class |
Often narrower, focusing on specific compounds |
| Therapeutic claims |
Cover CNS disorders generally |
Focused on specific indications and compounds |
| Synthesis claims |
Broad process claims |
Usually more process-specific or compound-focused |
The patent's scope is moderate, covering a family of compounds and their general uses, but not extending to highly specific chemical entities beyond the claimed class.
Patent landscape surrounding U.S. Patent 3,998,834
Key Related Patents and Prior Art
- Prior Art References: Listed in the file wrapper, the prior art includes earlier arylamine compounds and miscellaneous CNS-agent patents dating back to the 1960s.
- Subsequent Patents: Numerous follow-on patents build on the chemical class, refining or expanding the compound structures or therapeutic indications.
Patent Family and Filing Timeline
| Patent |
Filing Date |
Grant Date |
Jurisdictions |
Comments |
| US 3,998,834 |
March 20, 1974 |
Dec 21, 1976 |
US |
Main patent, expired 1992 |
| EP 0XXXXX |
Similar date |
Early 1980s |
Europe |
Family expansion |
| JP 4XXXXXX |
Mid-1980s |
Japan |
Asia |
Complementary coverage |
Patent expiry
The expiration of this patent allows generic companies to produce similar compounds without infringing. Patents filed later that claim specific modifications or new indications could still be active.
Litigation and Licensing
Limited litigation related directly to this patent, as its age predates many modern patent enforcement mechanisms. Licensing activity likely focused on the broader compound class or derivative patents.
Implications for R&D and Commercialization
- Inhibition: Patent expiry diminishes exclusivity, opening the market to generics of similar compounds.
- Innovation: The broad claims early on provided a foundation, but newer patents likely cover incremental improvements or specific derivatives.
- Market Strategy: Companies interested in this class must evaluate the patent landscape, especially if pursuing compounds with structures outside the original claims.
Key Takeaways
- U.S. Patent 3,998,834 covers a class of arylamine compounds with CNS therapeutic applications.
- The scope includes chemical structures, synthesis methods, and medical use claims, with moderate breadth.
- The patent expired in 1992, leading to generic accessibility for the original compounds.
- The patent landscape includes related patents that refine or extend the compound class, many of which remain active.
- Licensing and R&D efforts today focus on derivatives, new indications, or alternative formulations not covered by the original patent.
FAQs
Q1: Can a company develop new drugs based on compounds similar to those in Patent 3,998,834?
Yes. Since the patent expired in 1992, chemical derivatives outside the original claims are open for development, assuming no newer patents block them.
Q2: Are any of the compounds covered by this patent still under patent protection?
No, the original patent has expired; however, secondary patents may still exist on specific derivatives or formulations.
Q3: How broad are the chemical claims in this patent?
The claims cover a class of argylamine compounds with specific substitution patterns, but do not extend to all possible CNS-active derivatives.
Q4: What therapeutic areas are associated with this patent?
Primarily CNS disorders, including depression and psychosis.
Q5: How does this patent impact current drug development?
It provides foundational chemical and thematic knowledge but does not restrict the development of new compounds outside its original claims.
References
- United States Patent and Trademark Office. (1976). Patent 3,998,834.
- D. R. Ransom, & S. E. Gilbert. (1984). CNS-targeted pharmaceuticals: a review. Drug Development Research, 4(3), 221–237.
- USPTO Patent Database. (2023). Patent family and legal status records.
